Good Practice Guideline for Preclinical Alcohol Research: The STRINGENCY Framework.

Curr Top Behav Neurosci

Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.

Published: August 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Research in the field of preclinical alcohol research, but also science in general, has a problem: Many published scientific results cannot be repeated. As a result, findings from preclinical research often do not translate well to humans, causing increasing disappointment and calls for restructuring of preclinical research, that is, better reproducibility of preclinical research. However, the replication crisis is an inherent problem in biomedical research. Replication failures are not only due to small experimental variations but are often the result of poor methodology. In response to the replication crisis, numerous guidelines and recommendations have been proposed to promote transparency, rigor, and reproducibility in scientific research. What is missing today is a framework that integrates all the confusing information that results from all these guidelines and recommendations. Here we present STRINGENCY, an integrative approach to good practice guidelines for preclinical alcohol research, which can also apply to behavioral research in general and which aims to improve preclinical research to better prepare it for translation and minimize the "valley of death" in translational research. STRINGENCY includes systematic review and, when possible, meta-analysis prior to study design, sample size calculation, preregistration, multisite experiments, scientific data management (FAIR), reporting of data using ARRIVE, generalization of research data, and transparent publications that allow reporting of null results. We invite the scientific community to adopt STRINGENCY to improve the reliability and impact of preclinical alcohol research.

Download full-text PDF

Source
http://dx.doi.org/10.1007/7854_2024_484DOI Listing

Publication Analysis

Top Keywords

preclinical alcohol
16
good practice
8
preclinical
8
preclinical better
8
replication crisis
8
guidelines recommendations
8
practice guideline
4
guideline preclinical
4
alcohol
4
stringency
4

Similar Publications

Sodium Orthovanadate (SOV) mitigates alcohol & alcohol plus high-fat diet (HFD)-induced hepatotoxicity in rats.

Cell Mol Biol (Noisy-le-grand)

September 2025

Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.

Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.

View Article and Find Full Text PDF

Purpose: Alcohol use disorder (AUD) and mild traumatic brain injury (mTBI) have a bidirectional, synergistic, and complicated relationship. Although it is difficult to definitively say that mTBI causes AUD, certain biological mechanisms that occur after trauma are also associated with hazardous alcohol use. Hazardous drinking is defined as any quantity or pattern of alcohol consumption that places people at risk for physical and/or psychological harm.

View Article and Find Full Text PDF

Therapeutic Potential of Agmatine in Alcohol Use Disorder: Preclinical insights and future directions.

Behav Brain Res

September 2025

Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, MS 441 002, India. Electronic address:

Alcohol Use Disorder (AUD) is a major global health challenge characterized by the recurrence of alcohol consumption, withdrawal symptoms, and significant social, economic, and health-related burdens. Despite conventional treatments such as cognitive behavioral therapy and medications like disulfiram and naltrexone, the majority of patients do not achieve adequate relief due to the multifactorial nature of this disorder, including mental health issues and neuroadaptive changes. Recent studies demonstrated that chronic alcohol consumption results in the disruption of both the production and signaling of endogenous agmatine, a neuromodulator synthesized from L-arginine.

View Article and Find Full Text PDF

Alcohol use disorders (AUDs) impose an enormous societal and financial burden, and world-wide, alcohol misuse is the 7th leading cause of premature death [1]. Despite this, there are currently only 3 FDA approved pharmacological approaches for the treatment of AUDs in the United States. The neurotensin (Nts) system has long been implicated in modulating behaviors associated with alcohol misuse.

View Article and Find Full Text PDF

Alcohol use disorder-associated pain: clinical and preclinical evidence.

Alcohol

September 2025

School of Neuroscience, Virginia Polytechnic and State University, 970 Washington Street SW, Blacksburg, VA, 24061, USA. Electronic address:

Alcohol Use Disorder (AUD) affects millions of people globally and is characterized by cycles of intoxication, withdrawal, and relapse. Convergent clinical and preclinical evidence strongly support the conclusion that AUD precipitates chronic pain marked by mechanical and thermal hypersensitivity, yet currently available FDA-approved therapeutics do not effectively manage AUD-associated pain. This review synthesizes clinical and preclinical evidence on AUD-associated pain, highlighting known phenomena of allodynia and hyperalgesia as well as small and/or large fiber neuropathy in patient subpopulations along with preclinical acute and chronic alcohol exposure paradigm-specific nociceptive phenotypes in rodents.

View Article and Find Full Text PDF